| NCT05207722 | CYNK-101 in Combination with Trastuzumab and Pembrolizumab in Patients with Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma | TERMINATED | PHASE1, PHASE2 | 2022-04-14 | 2024-02-15 | 2024-02-15 |
| NCT05218408 | CYNK-001 IV and IC in Combination With IL2 in Surgical Eligible Recurrent GBM With IDH-1 Wild Type | WITHDRAWN | PHASE1, PHASE2 | 2022-03-08 | 2024-05 | 2024-02 |
| NCT04489420 | Natural Killer Cell (CYNK-001) IV Infusion or IT Administration in Adults With Recurrent GBM | TERMINATED | PHASE1 | 2020-10-01 | 2021-08-10 | 2021-08-10 |
| NCT04365101 | Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19 | UNKNOWN | PHASE1, PHASE2 | 2020-05-13 | 2022-06-30 | 2021-12-30 |
| NCT04309084 | Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma | UNKNOWN | PHASE1 | 2020-05-12 | 2023-04-30 | 2023-01-31 |
| NCT04310592 | Natural Killer Cell (CYNK-001) Infusions in Adults with AML | TERMINATED | PHASE1 | 2020-03-12 | 2023-04-28 | 2023-01-20 |
| NCT02955550 | A Safety Study of Human Cord Blood Derived, Culture-expanded, Natural Killer Cell (PNK-007) Infusion With or Without Subcutaneous Recombinant Human Interleukin-2 (rhIL-2) Following Autologous Stem Cell Transplant for Multiple Myeloma (MM) | COMPLETED | PHASE1 | 2017-01-05 | 2019-06-04 | 2018-07-10 |
| NCT02781467 | A Safety Study of Human Cord Blood Derived, Culture Expanded Natural Killer Cell (PNK-007) Infusion With Subcutaneous Recombinant Human IL-2 (rhIL-2) in Adults With Relapsed and/or Refractory Acute Myeloid Leukemia (AML) | TERMINATED | PHASE1 | 2016-07-11 | 2017-12-07 | 2017-12-07 |
| NCT02552277 | A Efficacy and Safety Study of Intramuscular Injection of Human Placenta-Derived Cells (PDA-002) in Subjects With Diabetic Peripheral Neuropathy | COMPLETED | PHASE2 | 2015-10-27 | 2017-10-30 | 2017-03-07 |
| NCT02460081 | Safety, Hemodynamic Effects and Efficacy of Intramuscular PDA-002 in Subjects Who Have Diabetic Foot Ulcer With Peripheral Arterial Disease | WITHDRAWN | PHASE2 | 2015-06 | 2017-09 | 2017-09 |
| NCT02264288 | Efficacy and Safety of Intramuscular PDA-002 in Subjects Who Have Diabetic Foot Ulcer With and Without Peripheral Arterial Disease | TERMINATED | PHASE2 | 2014-10-23 | 2018-02-28 | 2018-02-28 |
| NCT01859117 | Study of Human Placenta-derived Cells (PDA002) to Evaluate the Safety and Effectiveness in Subjects With PAD and DFU | COMPLETED | PHASE1 | 2013-05 | 2016-10 | 2016-10 |
| NCT01769755 | A Randomized, Double-Blind, Placebo-Controlled Dose-Escalation Study to Determine the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Crohn's Disease | COMPLETED | PHASE1 | 2013-03 | 2014-11 | 2014-11 |
| NCT01440192 | Safety of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Adults With Stage II or III Pulmonary Sarcoidosis | TERMINATED | PHASE1 | 2011-09 | 2014-02 | 2014-02 |
| NCT01310114 | Study of Human Placenta-derived Cells (PDA001) to Evaluate the Safety and Effectiveness for Patients With Ischemic Stroke | TERMINATED | PHASE2 | 2011-03 | 2013-03 | 2013-03 |
| NCT01261403 | Study of Human Placenta-derived Cells (PDA001) to Evaluate the Safety and Effectiveness for Patients With Active Rheumatoid Arthritis | TERMINATED | PHASE2 | 2010-12 | 2013-09 | 2012-02 |
| NCT01155362 | A Multi-Center Study to Evaluate the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Adults With Moderate-to-Severe Crohn's Disease | COMPLETED | PHASE2 | 2010-08 | 2014-04 | 2012-02 |